AU Patent

AU2017274110A1 — Crystalline form of compound suppressing protein kinase activity, and application thereof

Assigned to Xcovery Holdings Inc · Expires 2019-01-24 · 7y expired

What this patent protects

Provided are a compound as represented by structural formula (I) ({5-[(1

USPTO Abstract

Provided are a compound as represented by structural formula (I) ({5-[(1

Drugs covered by this patent

ensartinib-hydrochloride (ENSARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: AU2017274110A1
Jurisdiction: AU
Classification: —
Expires: 2019-01-24
Drug substance claim: No
Drug product claim: No
Assignee: Xcovery Holdings Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.